Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Acute coronary syndrome management

Ferguson JJ, Califf RM, Antman EM, et al, Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy primary results of the SYNERGY randomized trial. JAMA 2004 292 45-54,... [Pg.84]

FIGURE 2.2 Algorithm for patients with non-ST-elevation acute coronary syndrome managed by an early invasive strategy. (ACS, acute coronary syndrome UFH, unfractionated heparin PCI, percutaneous coronary intervention.)... [Pg.24]

Ray KK, Cannon CP (2005) The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46 1425-1430... [Pg.599]

Acute coronary syndrome For patients with acute coronary syndrome (unstable angina/non-Q-wave Ml) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or coronary artery bypass graft (CABG), clopidogrel has been shown to decrease the rate of a combined endpoint of cardiovascular death. Ml, or stroke, as well as the rate of a combined endpoint of cardiovascular death. Ml, stroke, or refractory ischemia. [Pg.108]

Palmer, S., M. Sculpher, M. Robinson Philips, L. Ginnelly, and D. Gary. 2005. Management of Non-ST-Elevation Acute Coronary Syndromes How Cost-Effective Are Glycoprotein Ilb/IIIa Antagonists in the UK National Health Service International Journal of Cardiology 100(2) 229-240. [Pg.310]

Indications Treatment of patients with acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). [Pg.154]

Acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI) NA V6-(amino- iminomethyl)-V2 -(3-mercapto-l-oxo propyl-L-lysylglycyl -L-(alpha)-aspartyl- L-tryptophyl-L-prolyl -L-cysteinamide, cyclic (1-6)- disulfide NA... [Pg.572]

Clopidogrel inhibits platelet aggregation in a dose-dependent fashion, Several studies have shown that a loading dose of clopidogrel results in a much more rapid onset of platelet inhibition than that achieved by regular low doses (II), and recommended loading doses in acute coronary syndromes (ACS) management are 300 mg followed by 75 mg once daily. [Pg.61]

Although the role of these agents in the management of patients presenting with acute coronary syndromes (ACS)... [Pg.87]

Pifarre R, Scanlon PJ. Evidence-Based Management of the Acute Coronary Syndrome. Philadelphia Hanley Belfus, 2001 132. [Pg.107]

Bertrand ME, Simoons ML, Fox KA, et al, Task force on the management of acute coronary syndromes of the European Society of Cardiology, Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J 2002 23 1 809-1 840. [Pg.124]

The introduction of stents in interventional cardiology has added a new dimension in the management of acute coronary syndrome and related disorders. Moreover, stents are now commonly used in the management of vascular and... [Pg.613]

Maynard S J et al 2000 Management of acute coronary syndromes. British Medical Journal 321 220-223 Messerli F H 1995 This day 50 years ago. New England Journal of Medicine 332 1038-1039 (An account of the hypertension and stroke suffered by US President F D Roosevelt.)... [Pg.495]

Cannon CP. Management of Acute Coronary Syndromes. New Jersey Humana, 2003. [Pg.312]

De Winter RJ, Windhausen F, Cornel JH et al. Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005 353 1095. [Pg.313]

Following interventional procedures such as PTCA, catheterization with angiography can be used to evaluate efficacy of the intervention. In recurrent clinical syndromes, following a procedure, catheterization is used to help delineate a new management strategy. Catheterization is also now used commonly with PTCA and/or drug therapy in the management of acute coronary syndromes. [Pg.160]

Bosanquet N, Jonsson B, Fox KA. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein llb/Illa inhibitors in the management of acute coronary syndromes. Pharmacoeconomics 2003 21 1135-1152. [Pg.290]

See other pages where Acute coronary syndrome management is mentioned: [Pg.58]    [Pg.535]    [Pg.58]    [Pg.535]    [Pg.80]    [Pg.474]    [Pg.304]    [Pg.320]    [Pg.136]    [Pg.221]    [Pg.1]    [Pg.81]    [Pg.119]    [Pg.669]    [Pg.669]    [Pg.494]    [Pg.500]    [Pg.501]    [Pg.1656]    [Pg.120]    [Pg.123]    [Pg.261]    [Pg.315]   
See also in sourсe #XX -- [ Pg.19 ]



SEARCH



Coronary syndromes

© 2024 chempedia.info